Retraction: Evaluation of the effect of insulin resistance on pancreatic exocrine functions in obese patients with fecal elastase-1 levels

Yıl 2020, Cilt: 12 Sayı: 2, 1 - 6, 27.12.2020

Betül Börkü Uysal , Derya Argun

Öz

Objective
We aimed to show whether insufficiency develops in pancreatic exocrine functions since the insulin resistance period or not.
Method
We measured the anthropometric parameters, blood glucose profile parameters and fecal elastase-1 levels of a total of 65 obese patients with 35 insulin resistance and 30 without insulin resistance. Body mass indexes (BMI) Homeostasis of model assessment insulin resistance indexes (HOMA-IR) were calculated. Exocrine pancreatic insufficiency (EPI) was diagnosed with a fecal elastase-1 concentration (FE1) of less than 200 mg/g (ELISA).
Results
A statistically significant difference was not observed between the mean FE-1 levels between the groups. (p> 0.05). No statistically significant difference was observed between the distribution of mild and severe low FE-1 levels of the IR and Non-IR groups (p> 0.05) Table 3.
Conclusion
Our study revealed that the presence of insulin resistance does not cause any change in FE-1 levels in obese patients.

Anahtar Kelimeler

pancreatic exocrine function, insulin resistance, fecal elastase-1

Kaynakça

• 1. Yilmaztepe A, Ulukaya E, Ersoy C, Yilmaz M, Tokullugil HA. Investigation of fecal pancreatic elastase-1 levels in type 2 diabetic patients. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2005;16:75-80.
• 2. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Archives of internal medicine 2001;161:1989-96.
• 3. Radlinger B, Ramoser G, Kaser S. Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes. Current diabetes reports 2020;20:18.
• 4. Tu J, Zhang J, Ke L, et al. Endocrine and exocrine pancreatic insufficiency after acute pancreatitis: long-term follow-up study. BMC gastroenterology 2017;17:114.
• 5. Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes care 2008;31 Suppl 2:S165-9.
• 6. Dominici R, Franzini C. Fecal elastase-1 as a test for pancreatic function: a review. Clinical chemistry and laboratory medicine 2002;40:325-32.
• 7. (ADA) TADA. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes care 2020;43:S14-s31.
• 8. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obesity facts 2015;8:402-24.
• 9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
• 10. Altay M. Which factors determine exocrine pancreatic dysfunction in diabetes mellitus? World journal of gastroenterology 2019;25:2699-705.